Abstract
Six healthy volunteers participated in single- and multiple-dose pharmacokinetic studies of oral lorazepam. Following single 4-mg oral doses, peak plasma lorazepam concentrations ranging from 40 to 70 ng/ml were reached within 3 hr of the dose. Values of absorption half-life averaged 25min (range 10.3–42.7min), and elimination half-life (t 1/2β ) averaged 14.2 hr (range 8.4–23.9 hr). During 15 consecutive days of 3 mg per day administered in divided doses, accumulation to the steady-state condition was complete within several days of the initiation of therapy. Values of accumulation half-life (mean 21.1 hr) were slightly longer than t 1/2β , and the two were not well correlated. Observed accumulation ratios (mean 1.88) were very close to those predicted from the single-dose study (mean 1.77), but the correlation between the two (r=0.51) was not significant in the small sample size. “Washout” half-life values (mean 14.9 hr) were highly correlated with t 1/2β (r=0.92). Clearance of a single intravenous dose of antipyrine determined prior to the multiple- dose lorazepam study (mean 0.86 ml/min/kg) was essentially identical to that determined after the study (mean 0.87 ml/min/kg). Overall, the rate and extent of lorazepam accumulation during multiple dosage were reasonably well predicted by the single-dose kinetic study. However, accurate prediction for any specific individual was not always achieved. Stimulation or inhibition by lorazepam of its own clearance probably does not explain imprecise prediction, since single-dose t 1/2β .
Similar content being viewed by others
References
A. A. Kyriakopoulos. Bioavailability of lorazepam in humans. In L. A. Gottschalk and S. Merlis (eds.),Pharmacokinetics of Psychoactive Drugs: Blood Levels and Clinical Response, Spectrum Publications, New York, 1976, pp. 45–60.
D. J. Greenblatt, R. T. Schillings, A. A. Kyriakopoulos, R. I. Shader, S. F. Sisenwine, J. A. Knowles, and H. W. Ruelius. Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral14C-lorazepam.Clin. Pharmacol. Ther. 20:329–341 (1976).
D. J. Greenblatt, T. H. Joyce, W. H. Comer, J. A. Knowles, R. I. Shader, A. A. Kyriakopoulos, D. S. MacLaughlin, and H. W. Ruelius. Clinical pharmacokinetics of lorazepam. II. Intramuscular injection.Clin. Pharmacol. Ther. 21:222–230 (1977).
D. J. Greenblatt, W. H. Comer, H. W. Elliott, R. I. Shader, J. A. Knowles, and H. W. Ruelius. Clinical pharmacokinetics of lorazepam. III. Intravenous injection (preliminary results).J. Clin. Pharmacol. 17:490–494 (1977).
D. J. Greenblatt, R. I. Shader, K. Franke, D. S. MacLaughlin, J. S. Harmatz, M. D. Allen, A. Werner, and E. Woo. Pharmacokinetics and bioavailability of intravenous, intramuscular and oral lorazepam in humans.J. Pharm. Sci. 68:57–63 (1979).
D. J. Greenblatt and R. I. Shader.Benzodiazepines in Clinical Practice, Raven Press, New York, 1974.
D. J. Greenblatt and R. I. Shader. Pharmacotherapy of anxiety with benzodiazepines andΒ-adrenergic blockers. In M. A. Lipton, A. DiMascio, and K. F. Killam (eds.),Psychopharmacology: A Generation of Progress, Raven Press, New York, 1978, pp. 1381–1389.
D. J. Greenblatt, K. Franke, and R. I. Shader. Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography: Use in pharmacokinetic studies of lorazepam.J. Chromatog. 146:311–320 (1978).
B. B. Brodie, J. Axelrod, R. Soberman, and B. B. Levy. The estimation of antipyrine in biological materials.J. Biol. Chem. 179:25–29 (1949).
D. H. Huffman, D. W. Shoeman, and D. L. Azarnoff. Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man.Biochem. Pharmacol. 23:197–201 (1974).
R. A. Usanis.NLIN-Nonlinear Least Squares Estimation of Parameters (Library Services Series Document No. LSR-089-1), Triangle Universities Computation Center, Research Triangle Park, N.C., 1972.
H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokin. Biopharm. 2:123–148 (1974).
D. J. Greenblatt and J. Koch-Weser. Clinical pharmacokinetics.New Engt J. Med. 293:702–705, 964–970 (1975).
M. Gibaldi and D. Perrier.Pharmacokinetics, Dekker, New York, 1975.
J. G. Wagner.Fundamentals of Clinical Pharmacokinetics, Drug Intelligence Publications, Hamilton, Ill., 1975.
D. J. Greenblatt, R. I. Shader, K. Franke, and J. S. Harmatz. Pharmacokinetics of chlordiazepoxide and metabolites following single and multiple oral doses.Int. J. Clin. Pharmacol. Biopharm. 16:486–493 (1978).
A. J. Wilensky, R. H. Levy, A. S. Troupin, L. Moretti-Ojemann, and P. Friel. Clorazepate kinetics in treated epileptics.Clin. Pharmacol. Ther. 24:22–30 (1978).
J. G. Wagner. Drug accumulation.J. Clin. Pharmacol. 7:84–88 (1967).
J. C. K. Loo and S. Riegelman. Assessment of pharmacokinetic constants from postin- fusion blood curves obtained after i. v. infusion.J. Pharm. Sci. 59:53–55 (1970).
D. J. Greenblatt, J. A. Knowles, W. H. Comer, R. I. Shader, J. S. Harmatz, and H. W. Ruelius. Clinical pharmacokinetics of lorazepam. IV. Long-term oral administration.J. Clin. Pharmacol. 17:495–500 (1977).
I. H. Stevenson. Factors influencing antipyrine elimination.Br. J. Clin. Pharmacol. 4:261–265 (1977).
J. Hunter, W. R. Burnham, L. F. Chasseaud, and W. Down. Changes inD-glucaric acid excretion in relationship to alterations in the rate of antipyrine metabolism in man.Biochem. Pharmacol. 23:2480–2483 (1974).
E. S. Vesell, C. J. Lee, G. T. Passananti, and C. A. Shively. Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs.Pharmacology 10:317–329 (1973).
D. J. Greenblatt, K. Franke, and D. H. Huffman. Impairment of antipyrine clearance in humans by propranolol.Circulation 57:1161–1164 (1978).
E. S. Vesell, G. T. Passananti, J.-P. Viau, J. E. Epps, and F. J. DiCarlo. Effects of chronic prazepam administration on drug metabolism in man and rat.Pharmacology 7:197–206 (1972).
Author information
Authors and Affiliations
Additional information
This work was supported in part by Grant MH-12279 from the United States Public Health Service, by Grant 77-611 from the Foundations' Fund for Research in Psychiatry, and by a Grant-in-Aid from Wyeth Laboratories, Inc., Radnor, Pennsylvania.
Rights and permissions
About this article
Cite this article
Greenblatt, D.J., Allen, M.D., MacLaughlin, D.S. et al. Single- and multiple-dose kinetics of oral lorazepam in humans: The predictability of accumulation. Journal of Pharmacokinetics and Biopharmaceutics 7, 159–179 (1979). https://doi.org/10.1007/BF01059736
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059736